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The development of new treatments for cancer (and the
validation of old ones) depends on the rigorous demonstra-
tion ofimproved therapeutic index as compared with alterna-
tive strategies for management. Therapeutic advances in
cancer are, unfortunately, modest and infrequent, although,
modest advances can lead to the saving of many lives, as for
example in the treatment ofearly breast cancer with systemic
adjuvant therapy (Early Breast Cancer Trialists' Col-
laborative Group, 1992). Modest but important benefits can
be detected only through the recruitment of patients into
large randomised clinical trials (RCTs). Overall, a very small
proportion of patients undergoing treatment for cancer take
part in RCTs and thereby contribute to potential advances in
therapy. One of the possible reasons for poor accrual is
addressed in a paper published in this issue (Slevin et al.)
Slevin et al. found that, when patients were informed of a
hypothetical RCT for their disease, 42% of them would
agree to participate, 48% were undecided and only 10%
refused. These data suggest that very low rates of recruitment
do not occur because of patient refusal. By implication the
results of the study suggest problems elsewhere: failure of
physicians to seek recruitment into RCTs (Taylor et al.,
1984) and/or failure of the health care system to make it easy
for them to do so.
Should almost all cancer patients be offered participation
in a clinical trial? I do not think so. In some academic
medical centres, I have been told of the exact proportion of
patients entered on clinical trials, as though this were a grade
mark for the institution's success: we're running at A - this
month with 78%! My response is that I cannot frame enough
important questions to want to recruit 78% of my patients
into clinical trials. Consider, for example, patients with
metastatic breast cancer: a recent review of a decade of
abstracts published in the Proceedings of the American
Society ofClinical Oncology identified 114 RCTs for patients
with metastatic breast cancer of which only three showed
improved survival for experimental as compared with stan-
dard treatment (Chlebowski and Lillington, 1994); this pro-
portion is lower than the expected incidence of false-positive
trials. Improved survival is not the only end point of interest:
improved quality of life and/or decreased toxicity are also
important. However, while new drugs such as taxanes and
aggressive strategies such as high-dose chemotherapy with
autologous stem cell support should be evaluated in patients
with metastatic breast cancer, there can be little enthusiasm
for other comparisons of ABC vs XYZ which use response
and survival as major end points. Alphabet soup is not cheap
and can divert resources from more deserving research.
Unfortunately, many clinical trials are performed with lit-
tle or no chance of improving clinical practice. Reasons are
complex but include: (i) the ethic that to decry any form of
clinical research is to oppose motherhood; (ii) the relation-
ship between publication and academic or career advance-
ment, which may result in more attention being paid to
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quantity than to quality; and (iii) the nature of cooperative
groups, which encourages the performance of RCTs in all
areas to maintain the structure and funding of the group.
How might we determine whether the question being ad-
dressed in a clinical trial is important? One method is to ask
expert physicians if they would agree to entry into an RCT if
they had disease that would render them eligible. Mackillop
et al. (1989) demonstrated that 64% of expert oncologists (of
all disciplines) would agree to take part in a trial of lobec-
tomy vs segmentectomy for operable non-small cell lung
cancer (NCSLC), but only 19% of them would accept entry
into a Southwest Oncology Group trial which compared five
regimens of chemotherapy for treatment of metastatic
NSCLC. When non-medical people had been offered these
trials, acceptance was about equal initially, but acceptance of
the second trial decreased dramatically when they were told
of the preferences of expert physicians.
In another study we used expert physician surrogates to
define controversy about the management of localised (T2)
prostate cancer and about asymptomatic metastatic renal
cancer (Moore et al., 1990). We asked these physicians to
indicate their preferred management for each scenario, and
then asked them if they would be willing to (i) take part or
(ii) enter patients into clinical trials that either did or did not
address controversy. There was clear controversy between the
options of radical prostatectomy and radical radiotherapy for
T2 prostate cancer [a state of equipoise (Freedman, 1987)
with about 50% of physician surrogates opting for each],
suggesting that an RCT which compared these strategies was
of critical importance. Unfortunately, respondents had such
strong personal bias that only 30% would have agreed to
enter themselves on such a trial. When the results of the
survey were presented to respondents, 58% stated that they
would be willing to offer the trial to an eligible patient, but
one wonders about the success of recruitment in the face of
this personal bias (Moore et al., 1990). In the same survey
there was little controversy about the management of asymp-
tomatic metastatic renal cancer; respondents know that
nothing works. Despite this, more than 53% of them would
participate, and 60% would enter patients on a trial compar-
ing interferon alone with vinblastine plus interferon, two
treatments that were selected by none of them and which are
already known to convey minimal benefit. It is easy to do
uninteresting trials that compare similar modalities; it is
difficult to perform fundamental trials comparing radically
different strategies.
There are many important questions in oncology that
either are being or should be addressed by RCTs. Two of
them are the roles of pelvic radiotherapy and of portal vein
5-fluorouracil (5-FU) for perioperative treatment of rectal
cancer that are being addressed by the AXIS trial, (Gray et
al., 1991) cited by Slevin et al. (this issue) in which perhaps
4% ofeligble patients have been recruited in the UK. Others
concern the role of high-dose chemotherapy with stem cell
rescue as compared with conventional chemotherapy for
either metastatic breast cancer or as adjuvant therapy for
poor-prognosis primary breast cancer. Ongoing trials addres-
sing these questions have had slow accrual, which may reflectainica tials
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the difficulty of doctors in describing. and patients in accep-
ting. RCTs that compare radically different treatments: ABC
vs XYZ is much easier. Slevin et al. did not inform us of the
type of RCT presented in their survey. but one wonders if
their patients would have been as accepting of an RCT that
compared different modalities of treatment (e.g. surgery vs
radiation and chemotherapy) or treatments with major
differences in possible side-effects.
What can be cone to encourage recruitment into important
RCTs? I have the following suggestions.
(1) There should be greater selection of important RCTs
and rejection of unimportant ones. Some national or
international level of review should determine whether
an RCT truly addresses controversy and whether it has
a high probability of changing practice. Expert
physician surrogates might be used: 'Would you be
willing to enter this trial if you had the disease?' Novel
end points such as quality of life and cost-effectiveness
should also be encouraged.
(2) Trials should be kept as simple as possible and allow
some flexibility in evaluating strategies. This will allow
the participation of more physicians. thus facilitating
accrual and increasing the relevance of trial results to
routine oncologic practice (Yusuf et al.. 1990). This
strategy has been employed in designing the AXIS trial
for rectal cancer (Gray et al.. 1991). although the inves-
tigators mav have underestimated the conceptual barrier
of using intraportal 5-FU instead of the more familiar
intravenous 5-FU as one of the experimental
treatments.
(3) Participants in most trials are primarily Caucasian. with
higher than average levels of education. Strategies are
required to encourage the participation of under-
represented ethnic and socioeconomic groups. This will
also improve the generalisability of trial results.
(4) A combination of carrot and stick might encourage
physicians to approach patients about important RCTs.
Participation should be an expected component of
medical practice, as is maintaining clinical competence
and continuing medical education; it should assume
greater emphasis in undergraduate and postgraduate
medical education, and in advancement and promotion.
Failure to participate should require justification
(Segelov et al.. 1992).
(5) Those who fund health care. be this private or public.
should be educated that good clinical research is
cheaper than the uncritical adoption of unproven
treatments. There is no better example than the
preposterous use of high-dose chemotherapy and
autologous stem cell rescue for breast cancer through-
out the United States, (Antman et al.. 1994) with no
evidence of improved survival. Some insurance com-
panies will fund the procedure only as part of an RCT.
Although this raises ethical questions. it is evident that
resources for new treatments are limited. and it is cost-
effective to use these resources for rigorous evaluation
of new therapies with potential value. and for the de-
ployment of only these that convey clinical benefit. The
medical bywords of the 1990s are 'evidence-based
medicine': improvement of therapy and containment of
cost can find common ground here. Those who fund
health care should recognise that evidence depends on
research and that better and more cost-effective
medicine depends on RCTs that address important
questions.
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